$PMCB The assessment of report at the end of this period could drive Pharmacyte to file for Breakthrough Therapy Designation with FDA. PMCB
A breakthrough therapy is administered alone or in conjunction with other drugs to treat a grave or life threatening condition or disease, and initial clinical evidence implies that the medication may demonstrate substantial improvement compared to existing therapies on clinically significant endpoints. The FDA speeds up the development and assessment of the drug/therapy that has been stated a breakthrough therapy. Pancreatic cancer therapy designed by Pharmacyte has already been granted the Orphan Drug Designation from the European Medicines Agency and the FDA, so if the company manages to repeat the data from preceding clinical trials, it has a good chance of getting breakthrough therapy designation. http://www.mmjobserver.com/pharmacyte-biotech-inc-otcmktspmcb-targeting-to-produce-6-month-revolutionary-data/8961/ http://www.biolago.org/event/wissenschaft-trifft-wirtschaft-2016-wtw-innovationsschmiede-fuer-die-life-sciences-2/ LET'S HOLD AND ACCUMULATE Go $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.